145 related articles for article (PubMed ID: 34043677)
21. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
22. Retrospective comparison of stereotactic body radiotherapy versus intensity-modulated radiotherapy for stage III ultra-central squamous non-small-cell lung cancer.
Cong Y; Xuan L; Sun B; Wang J; Meng X; Zhang J; Xue J; Liu J; Shen G; Wu S
Future Oncol; 2019 Jun; 15(16):1855-1862. PubMed ID: 30950297
[No Abstract] [Full Text] [Related]
23. Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study.
Haslett K; Bayman N; Franks K; Groom N; Harden SV; Harris C; Hanna G; Harrow S; Hatton M; McCloskey P; McDonald F; Ryder WD; Faivre-Finn C
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1341-1348. PubMed ID: 33232772
[TBL] [Abstract][Full Text] [Related]
24. Involved-field radiotherapy is effective for patients 70 years old or more with early stage non-small cell lung cancer.
Yu HM; Liu YF; Yu JM; Liu J; Zhao Y; Hou M
Radiother Oncol; 2008 Apr; 87(1):29-34. PubMed ID: 18237795
[TBL] [Abstract][Full Text] [Related]
25. First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer.
Remick JS; Schonewolf C; Gabriel P; Doucette A; Levin WP; Kucharczuk JC; Singhal S; Pechet TTV; Rengan R; Simone CB; Berman AT
Clin Lung Cancer; 2017 Jul; 18(4):364-371. PubMed ID: 28162946
[TBL] [Abstract][Full Text] [Related]
26. Computed Tomography-Guided Interstitial High-Dose-Rate Brachytherapy in Combination With Regional Positive Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: A Phase 1 Clinical Trial.
Xiang L; Zhang JW; Lin S; Luo HQ; Wen QL; He LJ; Shang CL; Ren PR; Yang HR; Pang HW; Yang B; He HL; Chen Y; Wu JB
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1027-1034. PubMed ID: 26194678
[TBL] [Abstract][Full Text] [Related]
27. The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer.
Miller ED; Fisher JL; Haglund KE; Grecula JC; Xu-Welliver M; Bertino EM; He K; Shields PG; Carbone DP; Williams TM; Otterson GA; Bazan JG
J Thorac Oncol; 2018 Mar; 13(3):426-435. PubMed ID: 29326090
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
29. Comparison of toxicity and outcome in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy using IMRT or VMAT.
Wijsman R; Dankers F; Troost EGC; Hoffmann AL; van der Heijden EHFM; de Geus-Oei LF; Bussink J
Radiother Oncol; 2017 Feb; 122(2):295-299. PubMed ID: 27914680
[TBL] [Abstract][Full Text] [Related]
30. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
van den Hout WB; Kramer GW; Noordijk EM; Leer JW
J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients.
Ramaekers BL; Joore MA; Lueza B; Bonastre J; Mauguen A; Pignon JP; Le Pechoux C; De Ruysscher DK; ; Grutters JP
J Thorac Oncol; 2013 Oct; 8(10):1295-307. PubMed ID: 24457241
[TBL] [Abstract][Full Text] [Related]
32. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
33. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
[TBL] [Abstract][Full Text] [Related]
34. Radiotherapy improves the survival of patients with stage IV NSCLC: A propensity score matched analysis of the SEER database.
Zhang R; Li P; Li Q; Qiao Y; Xu T; Ruan P; Song Q; Fu Z
Cancer Med; 2018 Oct; 7(10):5015-5026. PubMed ID: 30239162
[TBL] [Abstract][Full Text] [Related]
35. Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer.
Wang EH; Corso CD; Rutter CE; Park HS; Chen AB; Kim AW; Wilson LD; Decker RH; Yu JB
J Clin Oncol; 2015 Sep; 33(25):2727-34. PubMed ID: 26101240
[TBL] [Abstract][Full Text] [Related]
36. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
[TBL] [Abstract][Full Text] [Related]
38. A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly.
Wang P; Zhang D; Guo XG; Li XM; Du LH; Sun BJ; Fang XQ; Guo YH; Guo J; An L; Qu GP; Liu CT
Medicine (Baltimore); 2016 Dec; 95(52):e5723. PubMed ID: 28033277
[TBL] [Abstract][Full Text] [Related]
39. Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study.
Martinussen HM; Reymen B; Wanders R; Troost EG; Dingemans AC; Öllers M; Houben R; De Ruysscher D; Lambin P; van Baardwijk A
Radiother Oncol; 2016 Nov; 121(2):322-327. PubMed ID: 27884510
[TBL] [Abstract][Full Text] [Related]
40. Trends in Postoperative Intensity-Modulated Radiation Therapy Use and Its Association With Survival Among Patients With Incompletely Resected Non-Small Cell Lung Cancer.
Yu B; Jun Ma S; Waldman O; Dunne-Jaffe C; Chatterjee U; Turecki L; Gill J; Yendamuri K; Iovoli A; Farrugia M; Singh AK
JAMA Netw Open; 2022 Sep; 5(9):e2230704. PubMed ID: 36074462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
